These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33177720)

  • 41. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
    Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade.
    Ribas A; Tumeh PC
    Clin Cancer Res; 2014 Oct; 20(19):4982-4. PubMed ID: 24970841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.
    El Osta B; Hu F; Sadek R; Chintalapally R; Tang SC
    Crit Rev Oncol Hematol; 2017 Nov; 119():1-12. PubMed ID: 29065979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyperprogressive disease with anti-PD-1 and anti-PD-L1.
    Brower V
    Lancet Oncol; 2016 Dec; 17(12):e527. PubMed ID: 27866860
    [No Abstract]   [Full Text] [Related]  

  • 46. Radiotherapy in combination with immune checkpoint inhibitors.
    De Ruysscher D; Reynders K; Van Limbergen E; Lambrecht M
    Curr Opin Oncol; 2017 Mar; 29(2):105-111. PubMed ID: 28085679
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.
    Kourie HR; Awada G; Awada A
    Immunotherapy; 2017 Jun; 9(8):647-657. PubMed ID: 28653570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer.
    Shah AY; Gao J; Siefker-Radtke AO
    Immunotherapy; 2017 Sep; 9(10):781-784. PubMed ID: 28877627
    [No Abstract]   [Full Text] [Related]  

  • 49. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resistance to PD1/PDL1 checkpoint inhibition.
    O'Donnell JS; Long GV; Scolyer RA; Teng MW; Smyth MJ
    Cancer Treat Rev; 2017 Jan; 52():71-81. PubMed ID: 27951441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cancer immunotherapy in patients with preexisting autoimmune disorders.
    Donia M; Pedersen M; Svane IM
    Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials.
    Egen JG; Ouyang W; Wu LC
    Immunity; 2020 Jan; 52(1):36-54. PubMed ID: 31940272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs].
    Gaultier De Saint Basile H; Poisson C; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Tartour E; De Guillebon E
    Bull Cancer; 2018 Dec; 105(12):1202-1208. PubMed ID: 30471959
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.
    Tian H; Kang Y; Song X; Xu Y; Chen H; Gong X; Zhang W; Xu Y; Xia X; Gao X; Yao W
    Cancer Lett; 2020 Apr; 476():170-182. PubMed ID: 32092355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer immunotherapy: The dark side of PD-1 receptor inhibition.
    Ludin A; Zon LI
    Nature; 2017 Dec; 552(7683):41-42. PubMed ID: 29143822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
    Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
    Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect and changes in PD‑1 expression of CD19 CAR‑T cells from T cells highly expressing PD‑1 combined with reduced‑dose PD‑1 inhibitor.
    Zhang R; Deng Q; Jiang YY; Zhu HB; Wang J; Zhao MF
    Oncol Rep; 2019 Jun; 41(6):3455-3463. PubMed ID: 30942469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape.
    Upadhaya S; Neftelinov ST; Hodge J; Campbell J
    Nat Rev Drug Discov; 2022 Jul; 21(7):482-483. PubMed ID: 35145263
    [No Abstract]   [Full Text] [Related]  

  • 60. Programmed cell death protein receptor and ligands in haematological malignancies - Current status.
    Sokołowski M; Sokołowska A; Mazur G; Butrym A
    Crit Rev Oncol Hematol; 2019 Mar; 135():47-58. PubMed ID: 30819446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.